A group of 29 international medical experts is calling for a major change in how we screen for heart disease. In a recent ...

I’m a generally healthy 60-year-old man. Last week, I had some abdominal cramping, and while I was on the toilet, I noted the abrupt onset of a ...

C, shares how she saved Dr Jacquelyn Lacera’s life from a near-fatal cardiovascular event while aboard a flight from Hawaii.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Current AF management guidelines have introduced the CARE treatment model to strengthen management ...

The identification and management of comorbidities are central to the care of patients with atrial fibrillation (AF). The ...

Research finds adults under 70 with atrial fibrillation have 21% higher dementia risk, with onset cases showing a dramatic 36 ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a challenge for Milestone Pharmaceutical in its 22 years. | The FDA has rejected ...

Milestone (WA: MMD )’s President and CEO, Joe Oliveto, expressed the company’s disappointment with the CRL but reaffirmed their commitment to CARDAMYST as a potential novel treatment for PSVT. The ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...